Clinical trials: Diffuse Large-Cell Lymphoma
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-Cell Lymphoma
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma.
- Trial name
- NCT02420210
- Testing
- Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Lymphoma, Small Intestine Cancer
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma tumors may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future.
- Trial name
- NCT00897923
- Testing
- radionuclide imaging, indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00101010
- Testing
- Filgrastim, Pegfilgrastim, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is an Open label, Phase Ⅰb Study of ATG-010 in Combination With ATG-008 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
- Trial name
- MATCH (NCT05354362)
- Testing
- ATG-010 and ATG-008
- Where
- 6 sites in China
- Volunteers
- 7 people
- Sponsor
- Antengene Corporation
Diffuse Large B Cell Lymphoma, Thrombosis
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Comparative Evaluation of Thrombotic Risk Models in DLBCL patients Objective: To assess the impact of thrombotic risk factors and compare the performance of existing predictive models (Khorana, Throly, Model IX) in Diffuse Large…
- Trial name
- PREDIC-TO (NCT06694779)
- Where
- Italy
- Volunteers
- 1,504 people
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
B-cell Lymphoma, Burkitt Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT).
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04491370
- Testing
- Polatuzumab vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Diffuse Large B Cell Lymphoma
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT07368270
- Testing
- Anti-PD1 armored CD19 CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Bryostatin and Vincristine in B-Cell Malignancies
This phase I trial is studying the side effects and best dose of bryostatin-1 when given together with vincristine in treating patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or multiple myeloma.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00003166
- Testing
- bryostatin 1, vincristine sulfate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
Non-Hodgkin's lymphoma has been studied in the Pediatric Branch for at least 20 years, during which time a number of different treatment protocols have been used.
- Trial name
- NCT00001301
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma (DLBCL)
DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma
Poor prognosis dufuse large B-cell lymphoma (DLBCL) represents 50% of all DLBCL with overall cure rates ranging from 50-60% with modern dose-dense immunochemotherapy regimens such as R-CHOP14.
- Trial name
- NCT01066429
- Testing
- Dexamethasone and dose-dense immunochemoterapy
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Principe de Asturias
Diffuse Large B-cell Lymphoma
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma
The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay.
- Trial name
- NCT01606605
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
RATIONALE: Listening to relaxing music during a bone marrow biopsy may be effective in reducing anxiety and pain. PURPOSE: This randomized clinical trial is studying how well music works in reducing anxiety and pain in adult…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00376922
- Testing
- music therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Wake Forest University Health Sciences
Diffuse Large B-Cell Lymphoma
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R)…
- Trial name
- Javelin DLBCL (NCT02951156)
- Testing
- Avelumab, Utomilumab, Rituximab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Diffuse Large B Cell Lymphoma (DLBCL), Indolent B-Cell Lymphomas
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown…
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Indolent B-Cell Lymphomas, Indolent B Cell Lymphoma
- Trial name
- REVERSE_2021 (NCT06822829)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
The purpose of this study is to evaluate pidilizumab and its effect, bad and/or good, on the immune system in relation to its ability to fight cancer cells.
- Trial name
- NCT02530125
- Testing
- Laboratory Biomarker Analysis, Pidilizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells.
- Trial name
- NCT01004718
- Testing
- Fludeoxyglucose F18, Computed Tomography, Positron emission tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Diffuse Large B-Cell Lymphoma
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Despite of the availability of treatment for this disease, this study is justified because no known therapies are really curative and it is necessary to look for new treatment options to improve the clinical outcome and prognosis…
- Trial name
- NCT00902525
- Testing
- 90Y-Ibritumomab Tiuxetan
- Where
- 12 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.